Evaluation
*
*

Thinking about the impact of this session on your patients, please offer an estimate of the:

*
%
*
/month
*
1 (Disagree)2345 (Agree)
Discuss the pharmacology and indications of medications approved in the year 2016-2017 for the management of patients with hematologic malignancies
Recall the pivotal clinical trial data considered by the FDA when approving new oncologics
Identify the signs and symptoms of serious or life-threatening adverse effects of newly approved oncology drugs
Describe the impact of these agents in advanced practice
*
1 (Low)2345 (High)
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
*
*